Management of Suspected Ovarian Masses in Premenopausal Women
Background
In premenopausal women, almost all ovarian masses are benign. The risk of malignancy in a symptomatic cyst is approximately 1:1000, rising to 3:1000 by age 50. Around 10% of suspected "ovarian" masses are ultimately non-ovarian in origin (e.g. paratubal cyst, hydrosalpinx, tubo-ovarian abscess, pelvic kidney). No single test or algorithm reliably distinguishes benign from malignant disease preoperatively, except germ cell tumours, which are flagged by elevated tumour markers.
Assessment: History, Examination and Tumour Markers
- Take a history focused on malignancy red flags (persistent bloating, early satiety, pelvic/abdominal pain, urinary urgency/frequency) and endometriosis symptoms; clinical examination has poor sensitivity (15–51%) but helps assess tenderness, mobility, nodularity and ascites.
- CA-125 is not required when ultrasound has already made a clear diagnosis of a simple cyst (Grade B). Its use in premenopausal women is limited by poor specificity: it is commonly raised by fibroids, endometriosis, adenomyosis and pelvic infection, and is a marker of epithelial ovarian cancer only — it is elevated in just 50% of early-stage epithelial disease. Only severe (stage III–IV) endometriosis typically raises CA-125 into the hundreds-to-thousands range.
- If CA-125 is raised but <200 IU/ml, investigate other differentials first.
- If CA-125 is >200 IU/ml, discuss with a gynaecological oncologist.
- Serial, rising CA-125 is more suggestive of malignancy than a single static high value.
- LDH, AFP and hCG should be measured in all women under 40 with a complex ovarian mass (Grade C) because of the possibility of a germ cell tumour.
Imaging and Risk Stratification
Transvaginal ultrasound is the single most effective imaging modality (Grade B); routine CT/MRI adds no sensitivity or specificity over TVS (Grade C).
Two risk-stratification approaches are endorsed:
- Risk of Malignancy Index (RMI I) = Ultrasound score (U) × Menopausal status (M) × serum CA-125 (IU/ml). U=0 for no suspicious features, U=1 for one feature, U=3 for two or more (from: multilocular cyst, solid areas, metastases, ascites, bilateral lesions); M=1 premenopausal, M=3 postmenopausal. A pooled cutoff of RMI ≥200 gives sensitivity 78% and specificity 87%, but RMI accuracy is reduced in premenopausal women because endometriomas and borderline tumours often raise CA-125 without malignancy.
- IOTA Simple Rules classify masses using ultrasound features alone (no CA-125 required) into benign (B-rules: unilocular, solid component <7mm, acoustic shadowing, smooth multilocular tumour <100mm, no blood flow) or malignant (M-rules: irregular solid tumour, ascites, ≥4 papillary structures, irregular multilocular-solid tumour ≥100mm, very strong blood flow), with reported sensitivity 95%/specificity 91%. Masses not clearly classifiable need specialist review.
Conservative vs Surgical Management
- Simple cysts <50mm: no follow-up needed — almost always physiological, resolving within 3 menstrual cycles.
- Simple cysts 50–70mm: yearly ultrasound follow-up.
- Simple cysts >70mm: consider MRI or surgical intervention.
- The combined oral contraceptive pill does not accelerate resolution of functional cysts (Grade A).
- Persistent or enlarging cysts are unlikely to be functional and generally warrant surgery, though there is no agreed evidence-based size cutoff (most studies used 50–60mm as an arbitrary ceiling for conservative management).
- Laparoscopy is the preferred surgical approach for presumed-benign masses (Grade A) — lower morbidity, faster recovery, more cost-effective than laparotomy. Laparotomy/mini-laparotomy may suit very large masses with solid components (e.g. large dermoids); cyst rupture during laparoscopy is more common above ~70mm.
- Needle aspiration is discouraged — high recurrence (53–84%) (Grade B).
- Spillage of cyst contents should be avoided (use a retrieval bag); specimen removal via the umbilical port is preferred over lateral ports (Grade A).
High-Yield Exam Points
- CA-125 is not routinely needed for a simple cyst on ultrasound — a classic distractor trap.
- CA-125 is unreliable in premenopausal women due to false positives from fibroids/endometriosis/PID/adenomyosis; it detects only ~50% of early-stage epithelial cancers.
- CA-125 >200 IU/ml → discuss with gynaecological oncology.
- Under-40s with a complex mass → check AFP, hCG, and LDH (germ cell tumour markers).
- RMI I = U × M × CA-125; cutoff ≥200 (sensitivity 78%, specificity 87%), but less reliable in premenopausal women.
- IOTA Simple Rules can risk-stratify without CA-125.
- Simple cyst thresholds: <50mm no follow-up, 50–70mm yearly scan, >70mm consider MRI/surgery.
- Laparoscopy is the gold-standard surgical approach for presumed-benign masses; aspiration is not recommended due to high recurrence.
Source: RCOG Green-top Guideline No. 62 (First edition published November 2011 (RCOG/BSGE joint guideline). Formal review was scheduled to commence in 2014; RCOG's guidance index lists a second edition as "in development" but no replacement text has been published as of this writing — treat the 2011 edition as the current version and re-verify before citing an up-to-date review date.)
Read the original on rcog.org.uk
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).